Fairfield Financial Advisors LTD Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Fairfield Financial Advisors LTD increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 7.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,068 shares of the company’s stock after acquiring an additional 3,605 shares during the quarter. Novo Nordisk A/S comprises approximately 2.1% of Fairfield Financial Advisors LTD’s portfolio, making the stock its 14th biggest position. Fairfield Financial Advisors LTD’s holdings in Novo Nordisk A/S were worth $6,200,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NVO. Rosenberg Matthew Hamilton grew its holdings in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the period. HM Payson & Co. grew its stake in Novo Nordisk A/S by 3.8% in the third quarter. HM Payson & Co. now owns 4,125 shares of the company’s stock worth $491,000 after purchasing an additional 150 shares during the period. Diversify Wealth Management LLC raised its holdings in Novo Nordisk A/S by 3.4% in the third quarter. Diversify Wealth Management LLC now owns 35,792 shares of the company’s stock worth $4,143,000 after purchasing an additional 1,183 shares in the last quarter. First Trust Direct Indexing L.P. lifted its position in Novo Nordisk A/S by 1.7% during the third quarter. First Trust Direct Indexing L.P. now owns 72,828 shares of the company’s stock valued at $8,672,000 after buying an additional 1,198 shares during the period. Finally, Highline Wealth Partners LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $285,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.9 %

Shares of Novo Nordisk A/S stock traded down $2.10 on Thursday, reaching $111.14. The company’s stock had a trading volume of 4,922,601 shares, compared to its average volume of 4,345,633. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The firm’s fifty day simple moving average is $125.25 and its two-hundred day simple moving average is $131.06. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $498.74 billion, a price-to-earnings ratio of 38.04, a P/E/G ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Equities analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.66%.

Analyst Upgrades and Downgrades

Several research firms recently commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.